This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Bristol-Myers Squibb Company and Pfizer, Inc.
Reference
Lopes RD, et al. Clinical and Economic Outcomes Among Non-Valvular Atrial Fibrillation Patients with Coronary Artery Disease and/or Peripheral Artery Disease. American Journal of Cardiology : 3 Mar 2021. Available from: URL: http://doi.org/10.1016/j.amjcard.2021.02.021
Rights and permissions
About this article
Cite this article
Apixaban lower risk of adverse outcomes, lower cost in non-valvular AF + CAD/PAD. PharmacoEcon Outcomes News 874, 6 (2021). https://doi.org/10.1007/s40274-021-7549-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7549-7